BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38138487)

  • 1. Insight into the Inhibitory Mechanism of Embryonic Ectoderm Development Subunit by Triazolopyrimidine Derivatives as Inhibitors through Molecular Dynamics Simulation.
    Ju J; Zhang H; Guan S; Liu C; Du J; Shen X; Wang S
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
    Zhu K; Du D; Yang R; Tao H; Zhang H
    Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Design of the Indole-Substituted Triazolopyrimidines as New EED-H3K27me3 Inhibitors for the Treatment of Lymphoma.
    Dong G; Zuo J; Yu J; Xu J; Gao G; Li GB; Zhao W; Yu B
    J Med Chem; 2023 Jan; 66(1):1063-1081. PubMed ID: 36580346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
    Cook N; Chen J; Zhou J; Wu D
    Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
    Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
    Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-323-3p regulates the activity of polycomb repressive complex 2 (PRC2) via targeting the mRNA of embryonic ectoderm development (Eed) gene in mouse embryonic stem cells.
    Zhang Y; Teng F; Luo GZ; Wang M; Tong M; Zhao X; Wang L; Wang XJ; Zhou Q
    J Biol Chem; 2013 Aug; 288(33):23659-65. PubMed ID: 23821546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
    He Y; Selvaraju S; Curtin ML; Jakob CG; Zhu H; Comess KM; Shaw B; The J; Lima-Fernandes E; Szewczyk MM; Cheng D; Klinge KL; Li HQ; Pliushchev M; Algire MA; Maag D; Guo J; Dietrich J; Panchal SC; Petros AM; Sweis RF; Torrent M; Bigelow LJ; Senisterra G; Li F; Kennedy S; Wu Q; Osterling DJ; Lindley DJ; Gao W; Galasinski S; Barsyte-Lovejoy D; Vedadi M; Buchanan FG; Arrowsmith CH; Chiang GG; Sun C; Pappano WN
    Nat Chem Biol; 2017 Apr; 13(4):389-395. PubMed ID: 28135237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.
    Li L; Zhang H; Zhang M; Zhao M; Feng L; Luo X; Gao Z; Huang Y; Ardayfio O; Zhang JH; Lin Y; Fan H; Mi Y; Li G; Liu L; Feng L; Luo F; Teng L; Qi W; Ottl J; Lingel A; Bussiere DE; Yu Z; Atadja P; Lu C; Li E; Gu J; Zhao K
    PLoS One; 2017; 12(1):e0169855. PubMed ID: 28072869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2.
    Barnash KD; The J; Norris-Drouin JL; Cholensky SH; Worley BM; Li F; Stuckey JI; Brown PJ; Vedadi M; Arrowsmith CH; Frye SV; James LI
    ACS Comb Sci; 2017 Mar; 19(3):161-172. PubMed ID: 28165227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding Modes of Small-Molecule Inhibitors to the EED Pocket of PRC2.
    Huang D; Tian S; Qi Y; Zhang JZH
    Chemphyschem; 2020 Feb; 21(3):263-271. PubMed ID: 31816138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase.
    O' Donovan DH; Gregson C; Packer MJ; Greenwood R; Pike KG; Kawatkar S; Bloecher A; Robinson J; Read J; Code E; Hsu JH; Shen M; Woods H; Barton P; Fillery S; Williamson B; Rawlins PB; Bagal SK
    Bioorg Med Chem Lett; 2021 May; 39():127904. PubMed ID: 33684441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic regulation of embryonic ectoderm development in stem cell differentiation and transformation during ontogenesis.
    Huang L; Li F; Ye L; Yu F; Wang C
    Cell Prolif; 2023 Apr; 56(4):e13413. PubMed ID: 36727213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Split luciferase-based biosensors for characterizing EED binders.
    Li L; Feng L; Shi M; Zeng J; Chen Z; Zhong L; Huang L; Guo W; Huang Y; Qi W; Lu C; Li E; Zhao K; Gu J
    Anal Biochem; 2017 Apr; 522():37-45. PubMed ID: 28111304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PICOT binding to the polycomb group protein, EED, alters H3K27 methylation at the MYT1 PRC2 target gene.
    Pandya P; Pasvolsky R; Babichev Y; Braiman A; Witte S; Altman A; Isakov N
    Biochem Biophys Res Commun; 2019 Feb; 509(2):469-475. PubMed ID: 30595380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.
    Huang Y; Zhang J; Yu Z; Zhang H; Wang Y; Lingel A; Qi W; Gu J; Zhao K; Shultz MD; Wang L; Fu X; Sun Y; Zhang Q; Jiang X; Zhang J; Zhang C; Li L; Zeng J; Feng L; Zhang C; Liu Y; Zhang M; Zhang L; Zhao M; Gao Z; Liu X; Fang D; Guo H; Mi Y; Gabriel T; Dillon MP; Atadja P; Oyang C
    J Med Chem; 2017 Mar; 60(6):2215-2226. PubMed ID: 28092155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
    Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
    Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRC2 specifies ectoderm lineages and maintains pluripotency in primed but not naïve ESCs.
    Shan Y; Liang Z; Xing Q; Zhang T; Wang B; Tian S; Huang W; Zhang Y; Yao J; Zhu Y; Huang K; Liu Y; Wang X; Chen Q; Zhang J; Shang B; Li S; Shi X; Liao B; Zhang C; Lai K; Zhong X; Shu X; Wang J; Yao H; Chen J; Pei D; Pan G
    Nat Commun; 2017 Sep; 8(1):672. PubMed ID: 28939884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of SET/EED dual binders as innovative PRC2 inhibitors.
    Catalano R; Maruca A; Rocca R; Tassone P; Panzarella G; Costa G; Ortuso F; Alcaro S
    Future Med Chem; 2022 May; 14(9):609-621. PubMed ID: 35348013
    [No Abstract]   [Full Text] [Related]  

  • 20. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
    Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C
    J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.